Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases

Awiwi, Muhammad O.; Abudayyeh, Ala; Abdel-Wahab, Noha; Diab, Adi; Gjoni, Migena; Xu, Guofan; Vikram, Raghu; Elsayes, Khaled M.

doi:10.1007/s00330-022-09158-8

Cited by 9 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…65 We found that sIL-2R levels were much higher in patients scan can be increased in renal cortex in patients with ICI-associated AIN; however, this has not been rigorously studied. [66][67][68] More advanced imaging techniques that are being developed to diagnose inflammation; however, none have been systematically studied in this setting. 69 The fact that most tracers are renally excreted and accumulate in the collecting system affects the sensitivity and specificity of many imaging studies for identifying kidney inflammation.…”

Section: B Iomarker S Of Cong Enital C Tl A4 Defi Cien C Ymentioning

confidence: 99%

“…Imaging studies, such as positron emission tomography, that are routinely done to assess tumor response have also been proposed to help adjudicate ICI‐AIN. A few reports have shown that uptake of 18 F‐fluorodeoxyglucose (FDG) on positron emission tomography (PET) scan can be increased in renal cortex in patients with ICI‐associated AIN; however, this has not been rigorously studied 66–68 . More advanced imaging techniques that are being developed to diagnose inflammation; however, none have been systematically studied in this setting 69 .…”

Section: Using Imaging Techniques To Diagnose Ici‐ainmentioning

confidence: 99%

See 1 more Smart Citation

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease

Seethapathy

Mistry

Sise

2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryImmune checkpoint inhibitors (ICIs) have become a mainstay of cancer therapy, with over 80 FDA‐approved indications. Used in a variety of settings and in combination with each other and with traditional chemotherapies, the hyperactive immune response induced by ICIs can often lead to immune‐related adverse events in bystander normal tissues such as the kidneys, lungs, and the heart. In the kidneys, this immune‐related adverse event manifests as acute interstitial nephritis (ICI‐AIN). In the era of widespread ICI use, it becomes vital to understand the clinical manifestations of ICI‐AIN and the importance of prompt diagnosis and management of these complications. In this review, we delve into the clinical phenotypes of ICI‐AIN and how they differ from traditional drug‐induced AIN. We also detail what is known about the mechanistic underpinnings of ICI‐AIN and the important diagnostic and therapeutic implications behind harnessing those mechanisms to further our understanding of these events and to formulate effective treatment plans to manage ICI‐AIN.

show abstract

Section: B Iomarker S Of Cong Enital C Tl A4 Defi Cien C Ymentioning

confidence: 99%

Section: Using Imaging Techniques To Diagnose Ici‐ainmentioning

confidence: 99%

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease

Seethapathy

Mistry

Sise

2023

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…Білатеральне збільшення розмірів нирок, структурні зміни навколониркової тканини, та білатеральні клиноподібні гіпоехогенні кортикальні ділянки можуть спостерігатися у разі ІІКТ-пов`язаного ГН. На позитронно-емісійній томографії-КТ спостерігається дифузне підвищення поглинання радіоактивної речовини корковою речовиною та зниження радіоактивної активності в мисковій системі [31].…”

Section: Nephrology Schoolunclassified

Onconephrology: Acute kidney injury in cancer patients

Kolesnyk

2023

Ukr. J. Nephrol. and Dial.

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common complication of cancer, occurring in up to 50% of neoplastic patients during the natural course of their disease. Furthermore, it has a significant impact on key outcomes, such as overall prognosis, length of hospitalization, and costs. AKI in cancer patients has various causes, including patient-related, tumor-related, or treatment-related factors. Patient-related risk factors for AKI are similar to those in the general population. Tumor-related risk factors can involve compression, obstruction, direct kidney infiltration by the tumor, as well as precipitation, aggregation, crystallization, or misfolding of paraproteins in conditions like multiple myeloma. Treatment-related risk factors are the most commonly observed in clinical practice and can present as features of tumor lysis syndrome or, for example, immune checkpoint inhibitor-related AKI. In the absence of validated biomarkers for AKI, a multidisciplinary clinical approach involving oncologists, intensivists, nephrologists, or onconephrologists is essential. This approach incorporates thorough assessment, the use of appropriate preventive measures, and early intervention to reduce the incidence of AKI in cancer patients. Understanding the essence of preventive measures, timely initiation of treatment, and knowing when to terminate treatment will reduce the frequency of this life-threatening condition and improve the effectiveness of cancer treatment and the quality of life and life expectancy of cancer patients. This work aims to improve physicians' awareness of the latest data on the prevention, diagnosis, and treatment of AKI specifically related to oncopathology, tumor lysis syndrome, and acute kidney injury induced by cancer immunotherapy drugs.

show abstract

“…Bilateral increase in kidney size, new/increasing perinephric stranding, and bilateral wedge-shaped hypoenhancing cortical foci can occur in ICI--related nephritis. On PET-CT, a diffuse increase in radiotracer uptake throughout the renal cortex and a decrease in radiotracer activity in the renal pelvis can be seen 15 .…”

Section: They Work By Directly Inhibiting Immune Checkpoints Allowing...mentioning

confidence: 99%

“…On positron emission tomography-computerized tomography, a diffuse increase in radiotracer uptake throughout the renal cortex and a decrease in radiotracer activity in the renal pelvis can be seen. 15…”

Section: Aki Updatementioning

confidence: 99%

Onconephrology 2022: An Update

et al. 2022

View full text Add to dashboard Cite

Onconephrology is an upcoming and expanding subspecialty that deals with the intersections between hematology/oncology and nephrology. With the paradigm shift in the understanding of cancer immunobiology and mechanisms of onco-therapeutic drug toxicities, it is important for a nephrologist to have a sound understanding of this field. Over the last 5 years, there have been immense developments in our understanding of kidney related adverse events from various targeted, immuno and cellular-based therapies. Pathogenic mechanisms of electrolyte imbalance, hypertension (Onco-hypertension), and acute kidney injury from multiple forms of cancer therapies have been explored. Significant research has also been conducted in the field of transplant onconephrology. In this review, we have tried to assimilate the most recent updates in the last 2 years in this ever-growing and fascinating field.

show abstract

Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases

Cited by 9 publications

References 33 publications

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease

Onconephrology: Acute kidney injury in cancer patients

Onconephrology 2022: An Update

Contact Info

Product

Resources

About